Table 1 Characteristics of the male cancer survivors

From: Reproduction and marriage among male survivors of cancer in childhood, adolescence and young adulthood: a national cohort study

 

Age at diagnosis

Calendar year of diagnosis

 
 

Number (% of total number in age category)

Number (% of total number in diagnostic period)

 

Diagnostic group a

0–14 Years

15–19 Years

20–24 Years

1965–79

1980–94

1995–07

Total (%)

I. Leukemia

214 (26.1)

74 (10.4)

54 (4.7)

59 (23.9)

207 (15.4)

76 (6.9)

342 (12.7)

 Lymphoblastic leukemia

169

51

19

45

149

45

239

 Myeloid leukemia

18

16

23

3

33

21

57

 Leukemia, unspecified

27

7

12

11

25

10

46

II. Lymphoma

97 (11.8)

131 (4.5)

182 (15.7)

20 (8.1)

211 (15.7)

179 (16.4)

410 (15.3)

 Hodgkin lymphoma

41

76

127

7

116

121

244

 Non-Hodgkin lymphomab

50

55

53

8

93

57

158

 Lymphoma,unspecified

6

0

2

5

2

1

8

III. CNS neoplasmsc

214 (26.1)

122 (17.1)

150 (13.0)

60 (24.3)

260 (19.3)

166 (15.2)

486 (18.1)

 Low grade

148

76

96

44

170

106

320

 High grade

34

25

27

8

54

24

86

 Unspecified

32

21

27

8

36

36

80

IV. Sympathetic nervous system tumours

40 (4.9)

4 (0.6)

5 (0.4)

19 (7.6)

27 (2.0)

3 (0.3)

49 (1.8)

V.Retinoblastoma

39 (4.8)

0 (0)

0 (0)

17 (6.9)

22 (1.6)

0 (0)

39 (1.5)

VI. Renal tumours

56 (6.8)

1 (0.1)

4 (0.3)

30 (12.1)

27 (2.0)

4 (0.4)

61 (2.3)

VII. Hepatic tumours

8 (1.0)

3 (0.4)

3 (0.3)

5 (2.0)

8 (0.6)

1 (0.1)

14 (0.5)

VIII. Malignant bone tumours

38 (4.6)

61 (8.6)

29 (2.5)

7 (2.8)

77 (5.7)

44 (4.0)

128 (4.8)

IX. Soft tissue sarcomas

28 (3.4)

30 (4.2)

15 (1.3)

4 (1.6)

50 (3.7)

19 (1.7)

73 (2.7)

X. Germ cell and other gonadal neoplasms

39 (4.8)

179 (25.1)

516 (44.6)

16 (6.4)

284 (21.1)

434 (39.7)

734 (27.3)

XI. Carcinomas and other malignant epithelial neoplasms

Thyroid carcinomad

5 (0.6)

11 (1.5)

21 (1.8)

0 (0)

21 (1.6)

16 (1.5)

37 (1.4)

Malignant melanoma

13 (1.6)

40 (5.6)

77 (6.7)

3 (1.2)

69 (5.1)

58 (5.3)

130 (4.8)

Skin, non-melanomae

9 (1.1)

10 (1.4)

24 (2.1)

2 (0.8)

18 (1.3)

23 (2.1)

43 (1.6)

Colon

0 (0)

6 (0.8)

19 (1.6)

0 (0)

6 (0.4)

19 (1.7)

25 (0.9)

Urinary/bladder

4 (0.5)

5 (0.7)

9 (0.8)

2 (0.8)

9 (0.7)

7 (0.6)

18 (0.7)

XII. Other and unspecified malignant neoplasms

15 (1.8)

35 (4.9)

48 (4.2)

3 (1.2)

50 (3.7)

45 (4.1)

98 (3.6)

Total

819 (100)

712 (100)

1156 (100)

247 (100)

1346 (100)

1094 (100)

2687f (100)

  1. Abbreviations: CNS=central nervous system; ICD-7=International Classification of Disease, seventh edition; ICD-O-2=International Classification of diseases for oncology, second edition; MOTNAC=Manual of Tumor Nomenclature and Coding. Characteristics of the male cancer survivors (including overall and specific cancer sites), stratified according to age and time period of cancer diagnosis.
  2. aThe cancer site grouping used is a modified version of the International Classification of Childhood Cancer (Kramarova and Stiller, 1996), based on ICD-O-2 and MOTNAC morphology codes and ICD-7 topography codes.
  3. bIncluding Burkitt lymphoma.
  4. cThe grading of CNS tumours is based on the 2007 WHO classification of tumours of the CNS (Louis et al, 2007).
  5. dIncluding adrenal (endocrine) carcinoma (n=3).
  6. eExcluding basal cell carcinoma, site grouping based on ICD-7 site code 190.
  7. fIncluding 82 individuals with a secondary malignancy.
Back to article page